BRAF and melanoma: Finally, a phase II trial (Phase 2 Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapY, COWBOY) is studying the efficacy of 6-week induction therapy with vemurafenib + cobimetinib, followed by ipilimumab plus nivolumab, vs. upfront ipilimumab plus nivolumab in 83 patients with metastatic BRAF V600 melanoma [59].